#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Metabolic syndrome ( MetS ) is a cluster of disorders , including insulin resistance/hyperglycemia , visceral adiposity [ identified by large waistline ( WL ) or being overweight ] , atherogenic dyslipidemia ( e. g. , raised triglycerides ( TG ) or reduced high-density lipoprotein ( HDL ) ) , and endothelial dysfunction ( characterized by elevated blood pressures ) .
2-1	16-25	Metabolic	person|abstract[3]	new|new[3]	appos|coref|appos|coref	2-4[0_3]|4-36|2-4[0_3]|4-36
2-2	26-34	syndrome	abstract[3]	new[3]	_	_
2-3	35-36	(	_	_	_	_
2-4	37-41	MetS	abstract	giv	coref	2-7[5_0]
2-5	42-43	)	_	_	_	_
2-6	44-46	is	_	_	_	_
2-7	47-48	a	abstract[5]	giv[5]	coref	3-1[0_5]
2-8	49-56	cluster	abstract[5]	giv[5]	_	_
2-9	57-59	of	abstract[5]	giv[5]	_	_
2-10	60-69	disorders	abstract[5]|abstract[6]	giv[5]|new[6]	coref	13-47[133_6]
2-11	70-71	,	abstract[5]|abstract[6]	giv[5]|new[6]	_	_
2-12	72-81	including	abstract[5]|abstract[6]	giv[5]|new[6]	_	_
2-13	82-89	insulin	abstract[5]|abstract[6]|abstract[7]	giv[5]|new[6]|new[7]	_	_
2-14	90-114	resistance/hyperglycemia	abstract[5]|abstract[6]|abstract[7]	giv[5]|new[6]|new[7]	_	_
2-15	115-116	,	abstract[5]	giv[5]	_	_
2-16	117-125	visceral	abstract[5]|abstract[8]	giv[5]|new[8]	_	_
2-17	126-135	adiposity	abstract[5]|abstract[8]	giv[5]|new[8]	_	_
2-18	136-137	[	abstract[5]	giv[5]	_	_
2-19	138-148	identified	abstract[5]	giv[5]	_	_
2-20	149-151	by	abstract[5]	giv[5]	_	_
2-21	152-157	large	abstract[5]|quantity[9]	giv[5]|new[9]	_	_
2-22	158-167	waistline	abstract[5]|quantity[9]	giv[5]|new[9]	_	_
2-23	168-169	(	abstract[5]	giv[5]	_	_
2-24	170-172	WL	abstract[5]|abstract	giv[5]|new	_	_
2-25	173-174	)	abstract[5]	giv[5]	_	_
2-26	175-177	or	abstract[5]	giv[5]	_	_
2-27	178-183	being	abstract[5]	giv[5]	_	_
2-28	184-194	overweight	abstract[5]	giv[5]	_	_
2-29	195-196	]	abstract[5]	giv[5]	_	_
2-30	197-198	,	abstract[5]	giv[5]	_	_
2-31	199-210	atherogenic	abstract[5]|abstract[11]	giv[5]|new[11]	_	_
2-32	211-223	dyslipidemia	abstract[5]|abstract[11]	giv[5]|new[11]	_	_
2-33	224-225	(	_	_	_	_
2-34	226-228	e.	_	_	_	_
2-35	229-231	g.	_	_	_	_
2-36	232-233	,	_	_	_	_
2-37	234-240	raised	_	_	_	_
2-38	241-254	triglycerides	substance	new	_	_
2-39	255-256	(	_	_	_	_
2-40	257-259	TG	abstract	new	_	_
2-41	260-261	)	_	_	_	_
2-42	262-264	or	_	_	_	_
2-43	265-272	reduced	object[14]	new[14]	appos	2-47[0_14]
2-44	273-285	high-density	object[14]	new[14]	_	_
2-45	286-297	lipoprotein	object[14]	new[14]	_	_
2-46	298-299	(	_	_	_	_
2-47	300-303	HDL	object	giv	_	_
2-48	304-305	)	_	_	_	_
2-49	306-307	)	_	_	_	_
2-50	308-309	,	_	_	_	_
2-51	310-313	and	_	_	_	_
2-52	314-325	endothelial	abstract|abstract[17]	new|new[17]	_	_
2-53	326-337	dysfunction	abstract[17]	new[17]	_	_
2-54	338-339	(	_	_	_	_
2-55	340-353	characterized	_	_	_	_
2-56	354-356	by	_	_	_	_
2-57	357-365	elevated	abstract[19]	new[19]	_	_
2-58	366-371	blood	substance|abstract[19]	new|new[19]	coref	5-14
2-59	372-381	pressures	abstract[19]	new[19]	_	_
2-60	382-383	)	_	_	_	_
2-61	384-385	.	_	_	_	_

#Text=MetS significantly influences the development and deterioration of numerous diseases and is a crucial predictor of cardiovascular diseases .
3-1	386-390	MetS	substance	giv	coref	4-13
3-2	391-404	significantly	_	_	_	_
3-3	405-415	influences	_	_	_	_
3-4	416-419	the	abstract[21]	new[21]	_	_
3-5	420-431	development	abstract[21]	new[21]	_	_
3-6	432-435	and	_	_	_	_
3-7	436-449	deterioration	abstract[22]	new[22]	_	_
3-8	450-452	of	abstract[22]	new[22]	_	_
3-9	453-461	numerous	abstract[22]|abstract[23]	new[22]|new[23]	coref	3-17[26_23]
3-10	462-470	diseases	abstract[22]|abstract[23]	new[22]|new[23]	_	_
3-11	471-474	and	_	_	_	_
3-12	475-477	is	_	_	_	_
3-13	478-479	a	abstract[24]	new[24]	ana	4-20[0_24]
3-14	480-487	crucial	abstract[24]	new[24]	_	_
3-15	488-497	predictor	abstract[24]	new[24]	_	_
3-16	498-500	of	abstract[24]	new[24]	_	_
3-17	501-515	cardiovascular	abstract[24]|abstract|abstract[26]	new[24]|new|giv[26]	coref|coref	4-39[39_26]|4-39[39_26]
3-18	516-524	diseases	abstract[24]|abstract[26]	new[24]|giv[26]	_	_
3-19	525-526	.	_	_	_	_

#Text=Fortunately , numerous modifiable risk factors and corresponding practical intervention strategies regarding MetS were proposed , and hence , it is vital to identify the high-risk individuals nowadays to prevent the incidence and deterioration of metabolic derangement and its associated diseases .
4-1	527-538	Fortunately	_	_	_	_
4-2	539-540	,	_	_	_	_
4-3	541-549	numerous	abstract[28]	new[28]	_	_
4-4	550-560	modifiable	abstract[28]	new[28]	_	_
4-5	561-565	risk	abstract|abstract[28]	new|new[28]	_	_
4-6	566-573	factors	abstract[28]	new[28]	_	_
4-7	574-577	and	_	_	_	_
4-8	578-591	corresponding	abstract[30]	new[30]	_	_
4-9	592-601	practical	abstract[30]	new[30]	_	_
4-10	602-614	intervention	event|abstract[30]	new|new[30]	_	_
4-11	615-625	strategies	abstract[30]	new[30]	_	_
4-12	626-635	regarding	_	_	_	_
4-13	636-640	MetS	abstract	giv	coref	5-10
4-14	641-645	were	_	_	_	_
4-15	646-654	proposed	_	_	_	_
4-16	655-656	,	_	_	_	_
4-17	657-660	and	_	_	_	_
4-18	661-666	hence	_	_	_	_
4-19	667-668	,	_	_	_	_
4-20	669-671	it	abstract	giv	ana	4-39
4-21	672-674	is	_	_	_	_
4-22	675-680	vital	_	_	_	_
4-23	681-683	to	_	_	_	_
4-24	684-692	identify	_	_	_	_
4-25	693-696	the	person[33]	new[33]	_	_
4-26	697-706	high-risk	person[33]	new[33]	_	_
4-27	707-718	individuals	person[33]	new[33]	_	_
4-28	719-727	nowadays	_	_	_	_
4-29	728-730	to	_	_	_	_
4-30	731-738	prevent	_	_	_	_
4-31	739-742	the	abstract[34]	new[34]	_	_
4-32	743-752	incidence	abstract[34]	new[34]	_	_
4-33	753-756	and	_	_	_	_
4-34	757-770	deterioration	abstract[35]	new[35]	_	_
4-35	771-773	of	abstract[35]	new[35]	_	_
4-36	774-783	metabolic	abstract[35]|person|abstract[37]	new[35]|giv|new[37]	_	_
4-37	784-795	derangement	abstract[35]|abstract[37]	new[35]|new[37]	_	_
4-38	796-799	and	_	_	_	_
4-39	800-803	its	abstract|abstract[39]	giv|giv[39]	_	_
4-40	804-814	associated	abstract[39]	giv[39]	_	_
4-41	815-823	diseases	abstract[39]	giv[39]	_	_
4-42	824-825	.	_	_	_	_

#Text=Nevertheless , the conventional procedures for the confirmation of MetS have depended on blood assays , which largely lead to a resistive mentality toward the procedures and are therefore nonconducive to long-term follow-up .
5-1	826-838	Nevertheless	_	_	_	_
5-2	839-840	,	_	_	_	_
5-3	841-844	the	abstract[40]	new[40]	coref	5-25[46_40]
5-4	845-857	conventional	abstract[40]	new[40]	_	_
5-5	858-868	procedures	abstract[40]	new[40]	_	_
5-6	869-872	for	abstract[40]	new[40]	_	_
5-7	873-876	the	abstract[40]|event[41]	new[40]|new[41]	_	_
5-8	877-889	confirmation	abstract[40]|event[41]	new[40]|new[41]	_	_
5-9	890-892	of	abstract[40]|event[41]	new[40]|new[41]	_	_
5-10	893-897	MetS	abstract[40]|event[41]|event	new[40]|new[41]|giv	coref	6-10
5-11	898-902	have	_	_	_	_
5-12	903-911	depended	_	_	_	_
5-13	912-914	on	_	_	_	_
5-14	915-920	blood	substance|abstract[44]	giv|new[44]	coref|coref|coref|coref	22-24|22-24[221_44]|22-24|22-24[221_44]
5-15	921-927	assays	abstract[44]	new[44]	_	_
5-16	928-929	,	_	_	_	_
5-17	930-935	which	_	_	_	_
5-18	936-943	largely	_	_	_	_
5-19	944-948	lead	_	_	_	_
5-20	949-951	to	_	_	_	_
5-21	952-953	a	abstract[45]	new[45]	_	_
5-22	954-963	resistive	abstract[45]	new[45]	_	_
5-23	964-973	mentality	abstract[45]	new[45]	_	_
5-24	974-980	toward	abstract[45]	new[45]	_	_
5-25	981-984	the	abstract[45]|abstract[46]	new[45]|giv[46]	coref	22-17[219_46]
5-26	985-995	procedures	abstract[45]|abstract[46]	new[45]|giv[46]	_	_
5-27	996-999	and	_	_	_	_
5-28	1000-1003	are	_	_	_	_
5-29	1004-1013	therefore	_	_	_	_
5-30	1014-1026	nonconducive	_	_	_	_
5-31	1027-1029	to	_	_	_	_
5-32	1030-1039	long-term	event[47]	new[47]	_	_
5-33	1040-1049	follow-up	event[47]	new[47]	_	_
5-34	1050-1051	.	_	_	_	_

#Text=Therefore , there is a high probability of the MetS population being under-identified , especially those without an obese body shape .
6-1	1052-1061	Therefore	_	_	_	_
6-2	1062-1063	,	_	_	_	_
6-3	1064-1069	there	_	_	_	_
6-4	1070-1072	is	_	_	_	_
6-5	1073-1074	a	abstract[48]	new[48]	_	_
6-6	1075-1079	high	abstract[48]	new[48]	_	_
6-7	1080-1091	probability	abstract[48]	new[48]	_	_
6-8	1092-1094	of	abstract[48]	new[48]	_	_
6-9	1095-1098	the	abstract[48]|person[50]	new[48]|new[50]	ana	6-15[51_50]
6-10	1099-1103	MetS	abstract[48]|place|person[50]	new[48]|giv|new[50]	coref	7-18
6-11	1104-1114	population	abstract[48]|person[50]	new[48]|new[50]	_	_
6-12	1115-1120	being	_	_	_	_
6-13	1121-1137	under-identified	_	_	_	_
6-14	1138-1139	,	_	_	_	_
6-15	1140-1150	especially	person[51]	giv[51]	coref	15-23[150_51]
6-16	1151-1156	those	person[51]	giv[51]	_	_
6-17	1157-1164	without	person[51]	giv[51]	_	_
6-18	1165-1167	an	person[51]|abstract[53]	giv[51]|new[53]	_	_
6-19	1168-1173	obese	person[51]|abstract[53]	giv[51]|new[53]	_	_
6-20	1174-1178	body	person[51]|object|abstract[53]	giv[51]|new|new[53]	_	_
6-21	1179-1184	shape	person[51]|abstract[53]	giv[51]|new[53]	_	_
6-22	1185-1186	.	_	_	_	_

#Text=Consequently , there is a medical need for an easy , fast , and non-invasive method for MetS screening .
7-1	1187-1199	Consequently	_	_	_	_
7-2	1200-1201	,	_	_	_	_
7-3	1202-1207	there	_	_	_	_
7-4	1208-1210	is	_	_	_	_
7-5	1211-1212	a	abstract[54]	new[54]	_	_
7-6	1213-1220	medical	abstract[54]	new[54]	_	_
7-7	1221-1225	need	abstract[54]	new[54]	_	_
7-8	1226-1229	for	abstract[54]	new[54]	_	_
7-9	1230-1232	an	abstract[54]|abstract[55]	new[54]|new[55]	_	_
7-10	1233-1237	easy	abstract[54]|abstract[55]	new[54]|new[55]	_	_
7-11	1238-1239	,	abstract[54]|abstract[55]	new[54]|new[55]	_	_
7-12	1240-1244	fast	abstract[54]|abstract[55]	new[54]|new[55]	_	_
7-13	1245-1246	,	abstract[54]|abstract[55]	new[54]|new[55]	_	_
7-14	1247-1250	and	abstract[54]|abstract[55]	new[54]|new[55]	_	_
7-15	1251-1263	non-invasive	abstract[54]|abstract[55]	new[54]|new[55]	_	_
7-16	1264-1270	method	abstract[54]|abstract[55]	new[54]|new[55]	_	_
7-17	1271-1274	for	abstract[54]|abstract[55]	new[54]|new[55]	_	_
7-18	1275-1279	MetS	abstract[54]|abstract[55]|abstract|abstract[57]	new[54]|new[55]|giv|new[57]	coref|coref|coref|coref	14-19[140_57]|18-19[175_0]|14-19[140_57]|18-19[175_0]
7-19	1280-1289	screening	abstract[54]|abstract[55]|abstract[57]	new[54]|new[55]|new[57]	_	_
7-20	1290-1291	.	_	_	_	_

#Text=FibroScan is an ultrasound-based device equipped with the naval patented technology — Vibration-Controlled Transient Elastography ( VCTETM ) — that was originally developed to assess the level of liver fibrosis and cirrhosis by using a liver stiffness score ( the E score ) .
8-1	1292-1301	FibroScan	object	new	coref	8-3[59_0]
8-2	1302-1304	is	_	_	_	_
8-3	1305-1307	an	object[59]	giv[59]	coref	9-55[91_59]
8-4	1308-1324	ultrasound-based	object[59]	giv[59]	_	_
8-5	1325-1331	device	object[59]	giv[59]	_	_
8-6	1332-1340	equipped	_	_	_	_
8-7	1341-1345	with	_	_	_	_
8-8	1346-1349	the	abstract[60]	new[60]	appos	8-13[61_60]
8-9	1350-1355	naval	abstract[60]	new[60]	_	_
8-10	1356-1364	patented	abstract[60]	new[60]	_	_
8-11	1365-1375	technology	abstract[60]	new[60]	_	_
8-12	1376-1377	—	_	_	_	_
8-13	1378-1398	Vibration-Controlled	abstract[61]	giv[61]	_	_
8-14	1399-1408	Transient	abstract[61]|person	giv[61]|new	_	_
8-15	1409-1421	Elastography	abstract[61]	giv[61]	_	_
8-16	1422-1423	(	_	_	_	_
8-17	1424-1430	VCTETM	_	_	_	_
8-18	1431-1432	)	_	_	_	_
8-19	1433-1434	—	_	_	_	_
8-20	1435-1439	that	_	_	_	_
8-21	1440-1443	was	_	_	_	_
8-22	1444-1454	originally	_	_	_	_
8-23	1455-1464	developed	_	_	_	_
8-24	1465-1467	to	_	_	_	_
8-25	1468-1474	assess	_	_	_	_
8-26	1475-1478	the	abstract[63]	new[63]	_	_
8-27	1479-1484	level	abstract[63]	new[63]	_	_
8-28	1485-1487	of	abstract[63]	new[63]	_	_
8-29	1488-1493	liver	abstract[63]|object|object[65]	new[63]|new|new[65]	coref|coref	8-36|8-36
8-30	1494-1502	fibrosis	abstract[63]|object[65]	new[63]|new[65]	_	_
8-31	1503-1506	and	abstract[63]	new[63]	_	_
8-32	1507-1516	cirrhosis	abstract[63]|abstract	new[63]|new	_	_
8-33	1517-1519	by	_	_	_	_
8-34	1520-1525	using	_	_	_	_
8-35	1526-1527	a	abstract[69]	new[69]	appos	8-40[71_69]
8-36	1528-1533	liver	object|abstract[69]	giv|new[69]	coref	9-47
8-37	1534-1543	stiffness	abstract|abstract[69]	new|new[69]	coref	9-7[75_0]
8-38	1544-1549	score	abstract[69]	new[69]	_	_
8-39	1550-1551	(	_	_	_	_
8-40	1552-1555	the	abstract[71]	giv[71]	coref	9-14[79_71]
8-41	1556-1557	E	person|abstract[71]	new|giv[71]	coref	12-16
8-42	1558-1563	score	abstract[71]	giv[71]	_	_
8-43	1564-1565	)	_	_	_	_
8-44	1566-1567	.	_	_	_	_

#Text=Based on the transformation function of media stiffness and wave transmission velocity , the E score is calculated using a series of elastograms , which are simulated graphics of mathematical function of the time and depth of at least 10 shots of shear waves propagating through liver parenchyma transmitted using the probes mounted on the device .
9-1	1568-1573	Based	_	_	_	_
9-2	1574-1576	on	_	_	_	_
9-3	1577-1580	the	abstract[73]	new[73]	_	_
9-4	1581-1595	transformation	abstract|abstract[73]	new|new[73]	coref	10-6[94_0]
9-5	1596-1604	function	abstract[73]	new[73]	_	_
9-6	1605-1607	of	abstract[73]	new[73]	_	_
9-7	1608-1613	media	abstract[73]|abstract|abstract[75]	new[73]|new|giv[75]	_	_
9-8	1614-1623	stiffness	abstract[73]|abstract[75]	new[73]|giv[75]	_	_
9-9	1624-1627	and	abstract[73]	new[73]	_	_
9-10	1628-1632	wave	abstract[73]|abstract|abstract[78]	new[73]|new|new[78]	coref|coref	10-1[93_0]|10-1[93_0]
9-11	1633-1645	transmission	abstract[73]|abstract|abstract[78]	new[73]|new|new[78]	_	_
9-12	1646-1654	velocity	abstract[73]|abstract[78]	new[73]|new[78]	_	_
9-13	1655-1656	,	_	_	_	_
9-14	1657-1660	the	abstract[79]	giv[79]	coref	11-5[106_79]
9-15	1661-1662	E	abstract[79]	giv[79]	_	_
9-16	1663-1668	score	abstract[79]	giv[79]	_	_
9-17	1669-1671	is	_	_	_	_
9-18	1672-1682	calculated	_	_	_	_
9-19	1683-1688	using	_	_	_	_
9-20	1689-1690	a	object[80]	new[80]	_	_
9-21	1691-1697	series	object[80]	new[80]	_	_
9-22	1698-1700	of	object[80]	new[80]	_	_
9-23	1701-1712	elastograms	object[80]|abstract	new[80]|new	_	_
9-24	1713-1714	,	_	_	_	_
9-25	1715-1720	which	_	_	_	_
9-26	1721-1724	are	_	_	_	_
9-27	1725-1734	simulated	_	_	_	_
9-28	1735-1743	graphics	abstract[82]	new[82]	_	_
9-29	1744-1746	of	abstract[82]	new[82]	_	_
9-30	1747-1759	mathematical	abstract[82]|abstract[83]	new[82]|new[83]	_	_
9-31	1760-1768	function	abstract[82]|abstract[83]	new[82]|new[83]	_	_
9-32	1769-1771	of	abstract[82]|abstract[83]	new[82]|new[83]	_	_
9-33	1772-1775	the	abstract[82]|abstract[83]|time[84]	new[82]|new[83]|new[84]	_	_
9-34	1776-1780	time	abstract[82]|abstract[83]|time[84]	new[82]|new[83]|new[84]	_	_
9-35	1781-1784	and	abstract[82]|abstract[83]	new[82]|new[83]	_	_
9-36	1785-1790	depth	abstract[82]|abstract[83]|abstract	new[82]|new[83]|new	_	_
9-37	1791-1793	of	abstract[82]|abstract[83]	new[82]|new[83]	_	_
9-38	1794-1796	at	abstract[82]|abstract[83]|object[86]	new[82]|new[83]|new[86]	_	_
9-39	1797-1802	least	abstract[82]|abstract[83]|object[86]	new[82]|new[83]|new[86]	_	_
9-40	1803-1805	10	abstract[82]|abstract[83]|object[86]	new[82]|new[83]|new[86]	_	_
9-41	1806-1811	shots	abstract[82]|abstract[83]|object[86]	new[82]|new[83]|new[86]	_	_
9-42	1812-1814	of	abstract[82]|abstract[83]|object[86]	new[82]|new[83]|new[86]	_	_
9-43	1815-1820	shear	abstract[82]|abstract[83]|object[86]|abstract[87]	new[82]|new[83]|new[86]|new[87]	coref	12-10[114_87]
9-44	1821-1826	waves	abstract[82]|abstract[83]|object[86]|abstract[87]	new[82]|new[83]|new[86]|new[87]	_	_
9-45	1827-1838	propagating	_	_	_	_
9-46	1839-1846	through	_	_	_	_
9-47	1847-1852	liver	object|object[89]	giv|new[89]	coref|coref	10-23|10-23
9-48	1853-1863	parenchyma	object[89]	new[89]	_	_
9-49	1864-1875	transmitted	_	_	_	_
9-50	1876-1881	using	_	_	_	_
9-51	1882-1885	the	object[90]	new[90]	_	_
9-52	1886-1892	probes	object[90]	new[90]	_	_
9-53	1893-1900	mounted	_	_	_	_
9-54	1901-1903	on	_	_	_	_
9-55	1904-1907	the	object[91]	giv[91]	coref	13-41[0_91]
9-56	1908-1914	device	object[91]	giv[91]	_	_
9-57	1915-1916	.	_	_	_	_

#Text=The multiple-shot shear wave and elastogram transformation are implemented with controlled vibration , energy , and algorithms on the identical volume of liver tissue to ensure measurement reliability .
10-1	1917-1920	The	abstract[93]	giv[93]	_	_
10-2	1921-1934	multiple-shot	abstract[93]	giv[93]	_	_
10-3	1935-1940	shear	substance|abstract[93]	new|giv[93]	_	_
10-4	1941-1945	wave	abstract[93]	giv[93]	_	_
10-5	1946-1949	and	_	_	_	_
10-6	1950-1960	elastogram	abstract[94]	giv[94]	_	_
10-7	1961-1975	transformation	abstract[94]	giv[94]	_	_
10-8	1976-1979	are	_	_	_	_
10-9	1980-1991	implemented	_	_	_	_
10-10	1992-1996	with	_	_	_	_
10-11	1997-2007	controlled	abstract[95]	new[95]	_	_
10-12	2008-2017	vibration	abstract[95]	new[95]	_	_
10-13	2018-2019	,	_	_	_	_
10-14	2020-2026	energy	abstract	new	_	_
10-15	2027-2028	,	_	_	_	_
10-16	2029-2032	and	_	_	_	_
10-17	2033-2043	algorithms	abstract[97]	new[97]	_	_
10-18	2044-2046	on	abstract[97]	new[97]	_	_
10-19	2047-2050	the	abstract[97]|object[98]	new[97]|new[98]	_	_
10-20	2051-2060	identical	abstract[97]|object[98]	new[97]|new[98]	_	_
10-21	2061-2067	volume	abstract[97]|object[98]	new[97]|new[98]	_	_
10-22	2068-2070	of	abstract[97]|object[98]	new[97]|new[98]	_	_
10-23	2071-2076	liver	abstract[97]|object[98]|object|object[100]	new[97]|new[98]|giv|new[100]	coref|coref	11-12|11-12
10-24	2077-2083	tissue	abstract[97]|object[98]|object[100]	new[97]|new[98]|new[100]	_	_
10-25	2084-2086	to	_	_	_	_
10-26	2087-2093	ensure	_	_	_	_
10-27	2094-2105	measurement	abstract|abstract[102]	new|new[102]	coref|coref|coref|coref	12-15[117_0]|22-10[0_102]|12-15[117_0]|22-10[0_102]
10-28	2106-2117	reliability	abstract[102]	new[102]	_	_
10-29	2118-2119	.	_	_	_	_

#Text=The controlled attenuation parameter ( CAP ) score , denoting the liver steatosis , was embedded in instruments marketed after 2013 .
11-1	2120-2123	The	abstract[104]	new[104]	_	_
11-2	2124-2134	controlled	abstract[104]	new[104]	_	_
11-3	2135-2146	attenuation	abstract|abstract[104]	new|new[104]	_	_
11-4	2147-2156	parameter	abstract[104]	new[104]	_	_
11-5	2157-2158	(	abstract[106]	giv[106]	coref	12-1[111_106]
11-6	2159-2162	CAP	abstract|abstract[106]	new|giv[106]	coref	16-12
11-7	2163-2164	)	abstract[106]	giv[106]	_	_
11-8	2165-2170	score	abstract[106]	giv[106]	_	_
11-9	2171-2172	,	_	_	_	_
11-10	2173-2181	denoting	_	_	_	_
11-11	2182-2185	the	abstract[108]	new[108]	coref	16-5[153_108]
11-12	2186-2191	liver	object|abstract[108]	giv|new[108]	coref	13-49
11-13	2192-2201	steatosis	abstract[108]	new[108]	_	_
11-14	2202-2203	,	_	_	_	_
11-15	2204-2207	was	_	_	_	_
11-16	2208-2216	embedded	_	_	_	_
11-17	2217-2219	in	_	_	_	_
11-18	2220-2231	instruments	object	new	_	_
11-19	2232-2240	marketed	_	_	_	_
11-20	2241-2246	after	_	_	_	_
11-21	2247-2251	2013	time	new	_	_
11-22	2252-2253	.	_	_	_	_

#Text=The score is derived from the amplitude attenuations of ultrasonic waves detected simultaneously from the E score measurement .
12-1	2254-2257	The	abstract[111]	giv[111]	coref	12-17[0_111]
12-2	2258-2263	score	abstract[111]	giv[111]	_	_
12-3	2264-2266	is	_	_	_	_
12-4	2267-2274	derived	_	_	_	_
12-5	2275-2279	from	_	_	_	_
12-6	2280-2283	the	abstract[113]	new[113]	_	_
12-7	2284-2293	amplitude	abstract|abstract[113]	new|new[113]	_	_
12-8	2294-2306	attenuations	abstract[113]	new[113]	_	_
12-9	2307-2309	of	abstract[113]	new[113]	_	_
12-10	2310-2320	ultrasonic	abstract[113]|abstract[114]	new[113]|giv[114]	_	_
12-11	2321-2326	waves	abstract[113]|abstract[114]	new[113]|giv[114]	_	_
12-12	2327-2335	detected	_	_	_	_
12-13	2336-2350	simultaneously	_	_	_	_
12-14	2351-2355	from	_	_	_	_
12-15	2356-2359	the	abstract[117]	giv[117]	ana	13-3[0_117]
12-16	2360-2361	E	abstract|abstract[117]	giv|giv[117]	_	_
12-17	2362-2367	score	abstract|abstract[117]	giv|giv[117]	coref	16-12[157_0]
12-18	2368-2379	measurement	abstract[117]	giv[117]	_	_
12-19	2380-2381	.	_	_	_	_

#Text=Owing to its merits of being noninvasive , safe , rapid ( approximately 5 – 10 min for application ) , and the high-reproducibility of its automatically quantitative assessment outputs among operators , numerous studies have evaluated the performance of FibroScan in detecting chronic hepatitis and various other liver disorders .
13-1	2382-2387	Owing	_	_	_	_
13-2	2388-2390	to	_	_	_	_
13-3	2391-2394	its	abstract|abstract[119]	giv|new[119]	ana|coref|ana|coref	13-26|17-8[0_119]|13-26|17-8[0_119]
13-4	2395-2401	merits	abstract[119]	new[119]	_	_
13-5	2402-2404	of	_	_	_	_
13-6	2405-2410	being	_	_	_	_
13-7	2411-2422	noninvasive	_	_	_	_
13-8	2423-2424	,	_	_	_	_
13-9	2425-2429	safe	_	_	_	_
13-10	2430-2431	,	_	_	_	_
13-11	2432-2437	rapid	_	_	_	_
13-12	2438-2439	(	_	_	_	_
13-13	2440-2453	approximately	time[121]	new[121]	_	_
13-14	2454-2455	5	time[121]	new[121]	_	_
13-15	2456-2457	–	time[121]	new[121]	_	_
13-16	2458-2460	10	quantity|time[121]	new|new[121]	_	_
13-17	2461-2464	min	time[121]	new[121]	_	_
13-18	2465-2468	for	time[121]	new[121]	_	_
13-19	2469-2480	application	time[121]|abstract	new[121]|new	_	_
13-20	2481-2482	)	_	_	_	_
13-21	2483-2484	,	_	_	_	_
13-22	2485-2488	and	_	_	_	_
13-23	2489-2492	the	abstract[123]	new[123]	_	_
13-24	2493-2513	high-reproducibility	abstract[123]	new[123]	_	_
13-25	2514-2516	of	abstract[123]	new[123]	_	_
13-26	2517-2520	its	abstract[123]|abstract|abstract[126]	new[123]|giv|new[126]	_	_
13-27	2521-2534	automatically	abstract[123]|abstract[126]	new[123]|new[126]	_	_
13-28	2535-2547	quantitative	abstract[123]|abstract[126]	new[123]|new[126]	_	_
13-29	2548-2558	assessment	abstract[123]|abstract|abstract[126]	new[123]|new|new[126]	coref	17-27[165_0]
13-30	2559-2566	outputs	abstract[123]|abstract[126]	new[123]|new[126]	_	_
13-31	2567-2572	among	abstract[123]|abstract[126]	new[123]|new[126]	_	_
13-32	2573-2582	operators	abstract[123]|abstract[126]|person	new[123]|new[126]|new	_	_
13-33	2583-2584	,	_	_	_	_
13-34	2585-2593	numerous	event[128]	new[128]	coref	16-1[151_128]
13-35	2594-2601	studies	event[128]	new[128]	_	_
13-36	2602-2606	have	_	_	_	_
13-37	2607-2616	evaluated	_	_	_	_
13-38	2617-2620	the	abstract[129]	new[129]	_	_
13-39	2621-2632	performance	abstract[129]	new[129]	_	_
13-40	2633-2635	of	abstract[129]	new[129]	_	_
13-41	2636-2645	FibroScan	abstract[129]|object	new[129]|giv	coref	17-3
13-42	2646-2648	in	_	_	_	_
13-43	2649-2658	detecting	_	_	_	_
13-44	2659-2666	chronic	abstract[131]	new[131]	coref	15-6[0_131]
13-45	2667-2676	hepatitis	abstract[131]	new[131]	_	_
13-46	2677-2680	and	_	_	_	_
13-47	2681-2688	various	abstract[133]	giv[133]	coref	16-17[160_133]
13-48	2689-2694	other	abstract[133]	giv[133]	_	_
13-49	2695-2700	liver	object|abstract[133]	giv|giv[133]	coref	16-6
13-50	2701-2710	disorders	abstract[133]	giv[133]	_	_
13-51	2711-2712	.	_	_	_	_

#Text=In addition to bedside inspection in hospitalized patients , the virtue of its portability was also manifested in population outreach screening .
14-1	2713-2715	In	_	_	_	_
14-2	2716-2724	addition	_	_	_	_
14-3	2725-2727	to	_	_	_	_
14-4	2728-2735	bedside	_	_	_	_
14-5	2736-2746	inspection	event[134]	new[134]	_	_
14-6	2747-2749	in	event[134]	new[134]	_	_
14-7	2750-2762	hospitalized	event[134]|person[135]	new[134]|new[135]	coref	16-15[158_135]
14-8	2763-2771	patients	event[134]|person[135]	new[134]|new[135]	_	_
14-9	2772-2773	,	_	_	_	_
14-10	2774-2777	the	abstract[136]	new[136]	_	_
14-11	2778-2784	virtue	abstract[136]	new[136]	_	_
14-12	2785-2787	of	abstract[136]	new[136]	_	_
14-13	2788-2791	its	abstract[136]|abstract[137]	new[136]|new[137]	_	_
14-14	2792-2803	portability	abstract[136]|abstract[137]	new[136]|new[137]	_	_
14-15	2804-2807	was	_	_	_	_
14-16	2808-2812	also	_	_	_	_
14-17	2813-2823	manifested	_	_	_	_
14-18	2824-2826	in	_	_	_	_
14-19	2827-2837	population	abstract|abstract[140]	new|giv[140]	coref|coref	15-2[141_140]|15-2[141_140]
14-20	2838-2846	outreach	event|abstract[140]	new|giv[140]	_	_
14-21	2847-2856	screening	abstract[140]	giv[140]	_	_
14-22	2857-2858	.	_	_	_	_

#Text=In a street-based screening for hepatitis C virus ( HCV ) infection in drug users , the maneuver was excellently accepted by the target population .
15-1	2859-2861	In	_	_	_	_
15-2	2862-2863	a	abstract[141]	giv[141]	coref	20-12[196_141]
15-3	2864-2876	street-based	abstract[141]	giv[141]	_	_
15-4	2877-2886	screening	abstract[141]	giv[141]	_	_
15-5	2887-2890	for	abstract[141]	giv[141]	_	_
15-6	2891-2900	hepatitis	abstract[141]|abstract	giv[141]|giv	appos	15-7[143_0]
15-7	2901-2902	C	abstract[143]	giv[143]	appos	15-10[0_143]
15-8	2903-2908	virus	abstract[143]	giv[143]	_	_
15-9	2909-2910	(	_	_	_	_
15-10	2911-2914	HCV	abstract	giv	_	_
15-11	2915-2916	)	_	_	_	_
15-12	2917-2926	infection	event[145]	new[145]	_	_
15-13	2927-2929	in	event[145]	new[145]	_	_
15-14	2930-2934	drug	event[145]|substance|person[147]	new[145]|new|new[147]	_	_
15-15	2935-2940	users	event[145]|person[147]	new[145]|new[147]	_	_
15-16	2941-2942	,	_	_	_	_
15-17	2943-2946	the	event[148]	new[148]	_	_
15-18	2947-2955	maneuver	event[148]	new[148]	_	_
15-19	2956-2959	was	_	_	_	_
15-20	2960-2971	excellently	_	_	_	_
15-21	2972-2980	accepted	_	_	_	_
15-22	2981-2983	by	_	_	_	_
15-23	2984-2987	the	person[150]	giv[150]	coref	21-23[209_150]
15-24	2988-2994	target	abstract|person[150]	new|giv[150]	_	_
15-25	2995-3005	population	person[150]	giv[150]	_	_
15-26	3006-3007	.	_	_	_	_

#Text=Various studies have reported the liver steatosis grading cut-off points of CAP score in patients with different liver disorders with satisfactory accuracy .
16-1	3008-3015	Various	event[151]	giv[151]	_	_
16-2	3016-3023	studies	event[151]	giv[151]	_	_
16-3	3024-3028	have	_	_	_	_
16-4	3029-3037	reported	_	_	_	_
16-5	3038-3041	the	abstract[153]	giv[153]	coref	17-33[0_153]
16-6	3042-3047	liver	object|abstract[153]	giv|giv[153]	coref	16-18
16-7	3048-3057	steatosis	abstract[153]	giv[153]	_	_
16-8	3058-3065	grading	_	_	_	_
16-9	3066-3073	cut-off	abstract|abstract[155]	new|new[155]	_	_
16-10	3074-3080	points	abstract[155]	new[155]	_	_
16-11	3081-3083	of	abstract[155]	new[155]	_	_
16-12	3084-3087	CAP	abstract[155]|abstract|abstract[157]	new[155]|giv|giv[157]	_	_
16-13	3088-3093	score	abstract[155]|abstract[157]	new[155]|giv[157]	_	_
16-14	3094-3096	in	_	_	_	_
16-15	3097-3105	patients	person[158]	giv[158]	_	_
16-16	3106-3110	with	person[158]	giv[158]	_	_
16-17	3111-3120	different	person[158]|abstract[160]	giv[158]|giv[160]	coref	21-31[0_160]
16-18	3121-3126	liver	person[158]|object|abstract[160]	giv[158]|giv|giv[160]	coref	17-30
16-19	3127-3136	disorders	person[158]|abstract[160]	giv[158]|giv[160]	_	_
16-20	3137-3141	with	person[158]|abstract[160]	giv[158]|giv[160]	_	_
16-21	3142-3154	satisfactory	person[158]|abstract[160]|abstract[161]	giv[158]|giv[160]|new[161]	_	_
16-22	3155-3163	accuracy	person[158]|abstract[160]|abstract[161]	giv[158]|giv[160]|new[161]	_	_
16-23	3164-3165	.	_	_	_	_

#Text=Overall , FibroScan has a multitude of merits , such as being noninvasive , safe , fast , convenient , portable , and highly accurate in the assessment of liver stiffness and steatosis .
17-1	3166-3173	Overall	_	_	_	_
17-2	3174-3175	,	_	_	_	_
17-3	3176-3185	FibroScan	object	giv	coref	20-3[193_0]
17-4	3186-3189	has	_	_	_	_
17-5	3190-3191	a	abstract[163]	new[163]	_	_
17-6	3192-3201	multitude	abstract[163]	new[163]	_	_
17-7	3202-3204	of	abstract[163]	new[163]	_	_
17-8	3205-3211	merits	abstract[163]|abstract	new[163]|giv	_	_
17-9	3212-3213	,	_	_	_	_
17-10	3214-3218	such	_	_	_	_
17-11	3219-3221	as	_	_	_	_
17-12	3222-3227	being	_	_	_	_
17-13	3228-3239	noninvasive	_	_	_	_
17-14	3240-3241	,	_	_	_	_
17-15	3242-3246	safe	_	_	_	_
17-16	3247-3248	,	_	_	_	_
17-17	3249-3253	fast	_	_	_	_
17-18	3254-3255	,	_	_	_	_
17-19	3256-3266	convenient	_	_	_	_
17-20	3267-3268	,	_	_	_	_
17-21	3269-3277	portable	_	_	_	_
17-22	3278-3279	,	_	_	_	_
17-23	3280-3283	and	_	_	_	_
17-24	3284-3290	highly	_	_	_	_
17-25	3291-3299	accurate	_	_	_	_
17-26	3300-3302	in	_	_	_	_
17-27	3303-3306	the	abstract[165]	giv[165]	_	_
17-28	3307-3317	assessment	abstract[165]	giv[165]	_	_
17-29	3318-3320	of	abstract[165]	giv[165]	_	_
17-30	3321-3326	liver	abstract[165]|object|abstract[167]	giv[165]|giv|new[167]	coref|coref	18-16|18-16
17-31	3327-3336	stiffness	abstract[165]|abstract[167]	giv[165]|new[167]	_	_
17-32	3337-3340	and	abstract[165]	giv[165]	_	_
17-33	3341-3350	steatosis	abstract[165]|abstract	giv[165]|giv	coref	18-16[174_0]
17-34	3351-3352	.	_	_	_	_

#Text=A previous study found that the grades based on abdominal ultrasonography gave accurate information regarding liver steatosis and MetS in nonalcoholic , healthy people .
18-1	3353-3354	A	abstract[169]	new[169]	_	_
18-2	3355-3363	previous	abstract[169]	new[169]	_	_
18-3	3364-3369	study	abstract[169]	new[169]	_	_
18-4	3370-3375	found	_	_	_	_
18-5	3376-3380	that	_	_	_	_
18-6	3381-3384	the	abstract[170]	new[170]	_	_
18-7	3385-3391	grades	abstract[170]	new[170]	_	_
18-8	3392-3397	based	_	_	_	_
18-9	3398-3400	on	_	_	_	_
18-10	3401-3410	abdominal	object[171]	new[171]	_	_
18-11	3411-3426	ultrasonography	object[171]	new[171]	_	_
18-12	3427-3431	gave	_	_	_	_
18-13	3432-3440	accurate	abstract[172]	new[172]	_	_
18-14	3441-3452	information	abstract[172]	new[172]	_	_
18-15	3453-3462	regarding	_	_	_	_
18-16	3463-3468	liver	object|abstract[174]	giv|giv[174]	coref|coref|coref|coref	19-20|19-37[189_174]|19-20|19-37[189_174]
18-17	3469-3478	steatosis	abstract[174]	giv[174]	_	_
18-18	3479-3482	and	_	_	_	_
18-19	3483-3487	MetS	abstract[175]	giv[175]	coref	19-12[179_175]
18-20	3488-3490	in	abstract[175]	giv[175]	_	_
18-21	3491-3503	nonalcoholic	abstract[175]|person[176]	giv[175]|new[176]	coref	21-21[0_176]
18-22	3504-3505	,	abstract[175]|person[176]	giv[175]|new[176]	_	_
18-23	3506-3513	healthy	abstract[175]|person[176]	giv[175]|new[176]	_	_
18-24	3514-3520	people	abstract[175]|person[176]	giv[175]|new[176]	_	_
18-25	3521-3522	.	_	_	_	_

#Text=Moreover , considering the frequent coexistence and common pathological mechanisms of MetS and hepatopathy , such as steatohepatitis , liver inflammation , or the nonalcoholic fatty liver disease ( NAFLD ) , it was proposed that liver steatosis , especially NAFLD , could be a hepatic manifestation of MetS .
19-1	3523-3531	Moreover	_	_	_	_
19-2	3532-3533	,	_	_	_	_
19-3	3534-3545	considering	_	_	_	_
19-4	3546-3549	the	abstract[177]	new[177]	_	_
19-5	3550-3558	frequent	abstract[177]	new[177]	_	_
19-6	3559-3570	coexistence	abstract[177]	new[177]	_	_
19-7	3571-3574	and	_	_	_	_
19-8	3575-3581	common	abstract[178]	new[178]	_	_
19-9	3582-3594	pathological	abstract[178]	new[178]	_	_
19-10	3595-3605	mechanisms	abstract[178]	new[178]	_	_
19-11	3606-3608	of	abstract[178]	new[178]	_	_
19-12	3609-3613	MetS	abstract[178]|abstract[179]	new[178]|giv[179]	coref	19-49[0_179]
19-13	3614-3617	and	abstract[178]|abstract[179]	new[178]|giv[179]	_	_
19-14	3618-3629	hepatopathy	abstract[178]|abstract[179]|abstract	new[178]|giv[179]|new	_	_
19-15	3630-3631	,	abstract[178]	new[178]	_	_
19-16	3632-3636	such	abstract[178]	new[178]	_	_
19-17	3637-3639	as	abstract[178]	new[178]	_	_
19-18	3640-3655	steatohepatitis	abstract[178]|abstract	new[178]|new	_	_
19-19	3656-3657	,	abstract[178]	new[178]	_	_
19-20	3658-3663	liver	abstract[178]|object|abstract[183]	new[178]|giv|new[183]	coref|coref	19-27|19-27
19-21	3664-3676	inflammation	abstract[178]|abstract[183]	new[178]|new[183]	_	_
19-22	3677-3678	,	abstract[178]	new[178]	_	_
19-23	3679-3681	or	abstract[178]	new[178]	_	_
19-24	3682-3685	the	abstract[178]	new[178]	_	_
19-25	3686-3698	nonalcoholic	abstract[178]	new[178]	_	_
19-26	3699-3704	fatty	abstract[178]	new[178]	_	_
19-27	3705-3710	liver	abstract[178]|object|abstract[185]	new[178]|giv|new[185]	appos|coref|appos|coref	19-30[0_185]|19-37|19-30[0_185]|19-37
19-28	3711-3718	disease	abstract[178]|abstract[185]	new[178]|new[185]	_	_
19-29	3719-3720	(	_	_	_	_
19-30	3721-3726	NAFLD	abstract	giv	ana	19-33
19-31	3727-3728	)	_	_	_	_
19-32	3729-3730	,	_	_	_	_
19-33	3731-3733	it	abstract	giv	_	_
19-34	3734-3737	was	_	_	_	_
19-35	3738-3746	proposed	_	_	_	_
19-36	3747-3751	that	_	_	_	_
19-37	3752-3757	liver	object|abstract[189]	giv|giv[189]	appos|appos	19-40[190_189]|19-40[190_189]
19-38	3758-3767	steatosis	abstract[189]	giv[189]	_	_
19-39	3768-3769	,	_	_	_	_
19-40	3770-3780	especially	abstract[190]	giv[190]	coref	19-45[191_190]
19-41	3781-3786	NAFLD	abstract[190]	giv[190]	_	_
19-42	3787-3788	,	_	_	_	_
19-43	3789-3794	could	_	_	_	_
19-44	3795-3797	be	_	_	_	_
19-45	3798-3799	a	abstract[191]	giv[191]	_	_
19-46	3800-3807	hepatic	abstract[191]	giv[191]	_	_
19-47	3808-3821	manifestation	abstract[191]	giv[191]	_	_
19-48	3822-3824	of	abstract[191]	giv[191]	_	_
19-49	3825-3829	MetS	abstract[191]|abstract	giv[191]|giv	coref	20-16
19-50	3830-3831	.	_	_	_	_

#Text=Therefore , the FibroScan is investigated to be an option for the frontline screening of MetS in participants of a self-paid health examination in Taiwan .
20-1	3832-3841	Therefore	_	_	_	_
20-2	3842-3843	,	_	_	_	_
20-3	3844-3847	the	object[193]	giv[193]	coref	21-18[0_193]
20-4	3848-3857	FibroScan	object[193]	giv[193]	_	_
20-5	3858-3860	is	_	_	_	_
20-6	3861-3873	investigated	_	_	_	_
20-7	3874-3876	to	_	_	_	_
20-8	3877-3879	be	_	_	_	_
20-9	3880-3882	an	abstract[194]	new[194]	_	_
20-10	3883-3889	option	abstract[194]	new[194]	_	_
20-11	3890-3893	for	abstract[194]	new[194]	_	_
20-12	3894-3897	the	abstract[194]|abstract[196]	new[194]|giv[196]	_	_
20-13	3898-3907	frontline	abstract[194]|organization|abstract[196]	new[194]|new|giv[196]	_	_
20-14	3908-3917	screening	abstract[194]|abstract[196]	new[194]|giv[196]	_	_
20-15	3918-3920	of	abstract[194]|abstract[196]	new[194]|giv[196]	_	_
20-16	3921-3925	MetS	abstract[194]|abstract[196]|object	new[194]|giv[196]|giv	coref	21-35
20-17	3926-3928	in	abstract[194]	new[194]	_	_
20-18	3929-3941	participants	abstract[194]|person[198]	new[194]|new[198]	_	_
20-19	3942-3944	of	abstract[194]|person[198]	new[194]|new[198]	_	_
20-20	3945-3946	a	abstract[194]|person[198]|event[200]	new[194]|new[198]|new[200]	_	_
20-21	3947-3956	self-paid	abstract[194]|person[198]|event[200]	new[194]|new[198]|new[200]	_	_
20-22	3957-3963	health	abstract[194]|person[198]|abstract|event[200]	new[194]|new[198]|new|new[200]	_	_
20-23	3964-3975	examination	abstract[194]|person[198]|event[200]	new[194]|new[198]|new[200]	_	_
20-24	3976-3978	in	abstract[194]|person[198]|event[200]	new[194]|new[198]|new[200]	_	_
20-25	3979-3985	Taiwan	abstract[194]|person[198]|event[200]|place	new[194]|new[198]|new[200]|new	_	_
20-26	3986-3987	.	_	_	_	_

#Text=To the best of our knowledge , this is the first study to explore the utility of FibroScan in identifying people from the general population who have physical status and disorders that fulfill the MetS criteria .
21-1	3988-3990	To	_	_	_	_
21-2	3991-3994	the	_	_	_	_
21-3	3995-3999	best	_	_	_	_
21-4	4000-4002	of	_	_	_	_
21-5	4003-4006	our	person|abstract[203]	acc|new[203]	ana|ana	21-8[0_203]|21-8[0_203]
21-6	4007-4016	knowledge	abstract[203]	new[203]	_	_
21-7	4017-4018	,	_	_	_	_
21-8	4019-4023	this	abstract	giv	coref	21-10[205_0]
21-9	4024-4026	is	_	_	_	_
21-10	4027-4030	the	abstract[205]	giv[205]	_	_
21-11	4031-4036	first	abstract[205]	giv[205]	_	_
21-12	4037-4042	study	abstract[205]	giv[205]	_	_
21-13	4043-4045	to	_	_	_	_
21-14	4046-4053	explore	_	_	_	_
21-15	4054-4057	the	abstract[206]	new[206]	_	_
21-16	4058-4065	utility	abstract[206]	new[206]	_	_
21-17	4066-4068	of	abstract[206]	new[206]	_	_
21-18	4069-4078	FibroScan	abstract[206]|object	new[206]|giv	_	_
21-19	4079-4081	in	_	_	_	_
21-20	4082-4093	identifying	_	_	_	_
21-21	4094-4100	people	person	giv	_	_
21-22	4101-4105	from	_	_	_	_
21-23	4106-4109	the	person[209]	giv[209]	_	_
21-24	4110-4117	general	person[209]	giv[209]	_	_
21-25	4118-4128	population	person[209]	giv[209]	_	_
21-26	4129-4132	who	_	_	_	_
21-27	4133-4137	have	_	_	_	_
21-28	4138-4146	physical	abstract[210]	new[210]	_	_
21-29	4147-4153	status	abstract[210]	new[210]	_	_
21-30	4154-4157	and	_	_	_	_
21-31	4158-4167	disorders	abstract	giv	_	_
21-32	4168-4172	that	_	_	_	_
21-33	4173-4180	fulfill	_	_	_	_
21-34	4181-4184	the	abstract[213]	new[213]	_	_
21-35	4185-4189	MetS	abstract|abstract[213]	giv|new[213]	coref	22-14
21-36	4190-4198	criteria	abstract[213]	new[213]	_	_
21-37	4199-4200	.	_	_	_	_

#Text=A subsequent objective was to explore its feasibility and reliability in screening for MetS without performing any simultaneous invasive procedures , such as blood assays .
22-1	4201-4202	A	abstract[214]	new[214]	ana	22-7[0_214]
22-2	4203-4213	subsequent	abstract[214]	new[214]	_	_
22-3	4214-4223	objective	abstract[214]	new[214]	_	_
22-4	4224-4227	was	_	_	_	_
22-5	4228-4230	to	_	_	_	_
22-6	4231-4238	explore	_	_	_	_
22-7	4239-4242	its	abstract|abstract[216]	giv|new[216]	_	_
22-8	4243-4254	feasibility	abstract[216]	new[216]	_	_
22-9	4255-4258	and	_	_	_	_
22-10	4259-4270	reliability	abstract	giv	_	_
22-11	4271-4273	in	_	_	_	_
22-12	4274-4283	screening	_	_	_	_
22-13	4284-4287	for	_	_	_	_
22-14	4288-4292	MetS	object	giv	_	_
22-15	4293-4300	without	_	_	_	_
22-16	4301-4311	performing	_	_	_	_
22-17	4312-4315	any	abstract[219]	giv[219]	_	_
22-18	4316-4328	simultaneous	abstract[219]	giv[219]	_	_
22-19	4329-4337	invasive	abstract[219]	giv[219]	_	_
22-20	4338-4348	procedures	abstract[219]	giv[219]	_	_
22-21	4349-4350	,	abstract[219]	giv[219]	_	_
22-22	4351-4355	such	abstract[219]	giv[219]	_	_
22-23	4356-4358	as	abstract[219]	giv[219]	_	_
22-24	4359-4364	blood	abstract[219]|substance|abstract[221]	giv[219]|giv|giv[221]	_	_
22-25	4365-4371	assays	abstract[219]|abstract[221]	giv[219]|giv[221]	_	_
22-26	4372-4373	.	_	_	_	_
